NIA Uses Genomatix in Stem Cell Research, Suggests Novel Transcription Factors for Stemness
News Mar 17, 2008
Genomatix Software with businesses in Munich, Germany and Ann Arbor, Michigan has released that the group of Kenneth R. Boheler at the National Institute on Aging, National Institutes of Health, Baltimore, MD published some remarkable work on embryonic stem (ES) cells.
In their work they first identified and validated ES cell predominant transcripts by SAGE and qRT-PCR methods. Then they employed extensive DNA promoter analysis based on the integrated Genomatix system in order to identify conserved cis-elements and putative trans-regulators. Framework analysis for promoter organization, as introduced by Genomatix, increased likeliness for functional significance of the candidate transcription factors.
Predictions were experimentally verified by Chromosomal Immunoprecipitation assays.
The study led to the novel identification of two transcription factors, B-Myb and Maz which are implicated either in the maintenance of the undifferentiated stem cell state or in early steps of differentiation.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.